Accès gratuit
Med Sci (Paris)
Volume 17, Numéro 12, Décembre 2001
Page(s) 1343 - 1348
Section Mini-Synthèses
Publié en ligne 15 décembre 2001
  1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100 : 57–70.
  2. Werner H, Le Roith D. New concepts in regulation and function of the insulin-like growth factors : implications for understanding normal growth and neoplasia. Cell Mol Life Sci 2000; 57 : 932–42.
  3. Adams TE, Epa VC, Garrett TP, Ward CW. Structure and function of the type 1 insulinlike growth factor receptor. Cell Mol Life Sci 2000; 57 : 1050–93.
  4. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 2000; 21 : 215–44.
  5. Resnik JL, Reichart DB, Huey K, Webster NJ, Seely BL. Elevated insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer. Cancer Res 1998; 58 : 1159–64.
  6. Andrews DW, Resnicoff M, Flanders AE,et al. Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas. J Clin Oncol 2001; 19 : 2189–200.
  7. Weiss B, Davidkova G, Zhou LW. Antisense RNA gene therapy for studying and modulating biological processes. Cell Mol Life Sci 1999; 55 : 334–58.
  8. Myers KJ, Dean NM. Sensible use of antisense : how to use oligonucleotides as research tools. Trends Pharmacol Sci 2000; 21 : 19–23.
  9. Trojan J, Johnson TR, Rudin SD, Ilan J, Tykocinski ML, Ilan J. Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA. Science 1993; 259 : 94–7.
  10. Resnicoff M, Sell C, Rubini M,et al. Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors. Cancer Res 1994; 54 : 2218–22.
  11. Rininsland F, Johnson TR, Chernicky CL, Schulze E, Burfeind P, Ilan J. Suppression of insulin-like growth factor type I receptor by a triple-helix strategy inhibits IGF-I transcription and tumorigenic potential of rat C6 glioblastoma cells. Proc Natl Acad Sci USA 1997; 94 : 5854–9.
  12. Lafarge-Frayssinet C, Duc HT, Frayssinet C,et al. Antisense insulin-like growth factor I transferred into a rat hepatoma cell line inhibits tumorigenesis by modulating major histocompatibility complex I cell surface expression. Cancer Gene Ther 1997; 4 : 276–85.
  13. Lee CT, Wu S, Gabrilovich D,et al. Antitumor effects of an adenovirus expressing antisense insulin-like growth factor I receptor on human lung cancer cell lines. Cancer Res 1996; 56 : 3038–41.
  14. Liu X, Turbyville T, Fritz A, Whitesell L. Inhibition of insulin-like growth factor I receptor expression in neuroblastoma cells induces the regression of established tumors in mice. Cancer Res 1998; 58 : 5432–8.
  15. Wraight CJ, White PJ, McKean SC,et al. Reversal of epidermal hyperproliferation in psoriasis by insulin-like growth factor I receptor antisense oligonucleotides. Nat Biotechnol 2000; 18 : 521–6.
  16. Akhtar S, Hughes MD, Khan A,et al. The delivery of antisense therapeutics. Adv Drug Deliv Rev 2000; 44 : 3–21.
  17. Resnicoff M. Antitumor effects elicited by antisense-mediated downregulation of the insulin-like growth factor I receptor (review). Int J Mol Med 1998; 1 : 883–8.
  18. Beutler A, Banck MS, Aguzzi A, Wedekind D, Hedrich HJ. Curing rat glioblastoma : immunotherapy or graft rejection ? Science 1997; 276 : 20–21.
  19. Upegui-Gonzalez LC, François JC, Ly A, Trojan J. The approach of triple helix formation in control of gene expression and the treatment of tumors expressing IGF-I. Adv Exp Med Biol 2000; 465 : 319–32.
  20. Liu Y, Wang H, Zhao J,et al. Enhancement of immunogenicity of tumor cells by cotransfection with genes encoding antisense insulin-like growth factor-1 and B7.1 molecules. Cancer Gene Ther 2000; 7 : 456–65.
  21. Chernicky CL, Yi L, Tan H, Gan SU, Ilan J. Treatment of human breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor inhibits cell growth, suppresses tumorigenesis, alters the metastatic potential, and prolongs survival in vivo. Cancer Gene Ther 2000; 7 : 384–95.
  22. Li SL, Liang SJ, Guo N, Wu AM, Fujita-Yamaguchi Y. Single-chain antibodies against human insulin-like growth factor I receptor : expression, purification, and effect on tumor growth. Cancer Immunol Immunother 2000; 49 : 243–52.
  23. Reiss K, Tu X, Romano G, Peruzzi F, Wang JY, Baserga R. Intracellular association of a mutant insulin-like growth factor receptor with endogenous receptors. Clin Cancer Res 2001; 7 : 2134–44.
  24. Prager D, Li HL, Asa S, Melmed S. Dominant negative inhibition of tumorigenesis in vivo by human insulin-like growth factor I receptor mutant. Proc Natl Acad Sci USA 1994; 91 : 2181–5.
  25. Pietrzkowski Z, Mulholland G, Gomella L, Jameson BA, Wernicke D, Baserga R. Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1. Cancer Res 1993; 53 : 1102–6.
  26. Navab R, Chevet E, Authier F, Di Guglielmo GM, Bergeron JJ, Brodt P. Inhibition of endosomal insulin-like growth factor-I processing by cysteine proteinase inhibitors blocks receptor-mediated functions. J Biol Chem 2001; 276 : 13644–9.
  27. Delafontaine P, Meng XP, Ku L, Du J. Regulation of vascular smooth muscle cell insulin-like growth factor I receptors by phosphorothioate oligonucleotides. Effects on cell growth and evidence that sense targeting at the ATG site increases receptor expression. J Biol Chem 1995; 270 : 14383–8.
  28. Ly A, Duc HT, Kalamarides M,et al. Human glioma cells transformed by IGF-I triple helix technology show immune and apoptotic characteristics determining cell selection for gene therapy of glioblastoma. Mol Pathol 2001; 54 : 230–9.

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.